🧬 Strategic Optionality: M&A Hygiene & Investor Fit | Mike Stadnisky Rerelease (Part 3/3)

episode

The Biotech Startups Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

The Art of True Happiness | Dr. Arthur Brooks 2h 49m · 14 Sep 2026 · Huberman Lab

The Chris Wolfe Podcast: The Power of Quality Supplements 48 min · 14 Sep 2026 · EyeCode Media

1208: TM Europe win the '26 Solheim Cup 1h 49m · 13 Sep 2026 · No Laying Up - Golf Podcast

MORNING TEA: Harry & Meghan's Brutal SNL Roast, Lady Gaga's Baby News & Dakota Johnson's New Man 8 min · 13 Sep 2026 · The Spill

"I don't think they have enough match winners."| First Thoughts - Brisbane vs Adelaide (14.09.26) 15 min · 13 Sep 2026 · SEN Breakfast

Full Show Podcast: 14 September 2026 1h 28m · 13 Sep 2026 · The Mike Hosking Breakfast

Report any issue

Source

Recorded04 May 2026

Publisherfeeds.fame.so ↗

Handlerec:18246033

Show notes

In this episode of The Biotech Startups Podcast, Jon Chee sits down with Mike Stadnisky, Managing Director of Thielsen Capital, a seed-stage life science tools syndicate. A veteran of four-plus M&A cycles as CEO of FlowJo and Phytonix, Mike walks through the mechanics founders most often get wrong: when to call in partnership favors, how shared customers become acquisition seeds, what IP and cap table hygiene should look like before a deal, and why a rigorous financial model is your most powerful negotiating tool.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in